A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA)
Advanced esophageal squamous cell cancer (ESCC) is frequently diagnosed in elderly patients. The impact of 2nd line chemotherapy is poorly defined. Recent data demonstrated effectiveness of checkpoint inhibitors in different squamous cell carcinomas. Therefore, we assess combined nivolumab/ipilimuma...
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Article (Journal) |
| Lenguaje: | inglés |
| Publicado: |
14 March 2019
|
| In: |
BMC cancer
Year: 2019, Volumen: 19 |
| ISSN: | 1471-2407 |
| DOI: | 10.1186/s12885-019-5446-2 |
| Acceso en línea: | Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s12885-019-5446-2
|
| Notas de Autor: | Nadja M. Meindl-Beinker, Johannes Betge, Tobias Gutting, Elke Burgermeister, Sebastian Belle, Tianzuo Zhan, Nadine Schulte, Martin Maenz, Matthias P. Ebert and Nicolai Haertel |
Search Result 1
A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA)
BioMed Central ; Springer 21 Mai 2019 Universitätsbibliothek Heidelberg 21 Mai 2019
- Resolving-System, kostenfrei, Volltext
- Resolving-System, kostenfrei, Volltext
- Verlag, kostenfrei, Volltext
Article (Journal)
Book/Monograph
Online Resource